
News & Resources
Latest from VVMF
Keep up to date on our latest announcements, events and the developments shaping advanced therapeutics.

News / 13 Oct 2026
Viral Vector Manufacturing Facility (VVMF) and Peter MacCallum CancerCentre (Peter Mac) sign Letter of Intent to advance novel CAR T-celltherapy with potential in multiple myeloma, solid tumours
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s only commercial viral vector Contract Development and Manufacturing Organisation (CDMO) and Peter MacCallum Cancer Centre (Peter Mac),...
Viral Vector Manufacturing Facility (VVMF) and Peter MacCallum CancerCentre (Peter Mac) sign Letter of Intent to advance novel CAR T-celltherapy with potential in multiple myeloma, solid tumours
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s only commercial viral vector Contract Development and Manufacturing Organisation (CDMO) and Peter...
Viral Vector Manufacturing Facility (VVMF) has been named one of Australia’s Best Workplaces™ in Biotechnology and Pharmaceutical 2026
Great Place To Work®, the global authority on workplace culture, has today announced that Viral Vector Manufacturing Facility Pty Ltd (VVMF) has been...
VVMF, Australia’s First Viral Vector CDMO Receives TGA Manufacturing Licence
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises that the...
VVMF and Optosleep sign Letter of Intent to advance AAV gene therapy development and manufacturing readiness in Australia
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s only commercial viral vector Contract Development and Manufacturing Organisation (CDMO) and Optosleep,...
Viral Vector Manufacturing Facility (VVMF) and Mirugen sign Letter of Intent to advance AAV-based gene therapy development in Australia
Viral Vector Manufacturing Facility Pty Ltd (VVMF) and Mirugen Pty Ltd (Mirugen) have co-signed a Letter of Intent (LoI) to...
DIVERSITY DISCLOSURE 2025-2026
Viral Vector Manufacturing Facility Pty. Ltd. (“VVMF”, “the Company”) has adopted a Diversity Policy. This Policy requires disclosure regarding: The...
Viral Vector Manufacturing Facility (VVMF) to attend ASGCT 2026
Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in the American Society of Gene and Cell Therapy’s...
Viral Vector Manufacturing Facility (VVMF) to attend ARM’s Cell and Gene Meeting on the Med 2026
Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in ARM’s Cell and Gene Meeting on the Med...
Viral Vector Manufacturing (VVMF) enters into licensing agreement with OXB, gaining access to the OXB AAV and LV viral vector platforms
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces...
Viral Vector Manufacturing Facility (VVMF) at Advanced Therapies Week 2026, San Diego
Viral Vector Manufacturing Facility Pty Ltd (VVMF) announces its participation at Advanced Therapies Week 2026, 9 – 12 February 2026,...
VVMF announces strategic collaboration with OXB, with view to licensing AAV and lentiviral vector platforms as first priority
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), has commenced...
Australia’s First Clinical and Commercial-Scale Viral Vector CDMO, VVMF, Opens in Sydney
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first and only clinical and commercial-scale viral vector Contract Development and Manufacturing...
Learn more about VVMF
Have questions about our latest news, events, or industry activities?
We’d be happy to connect.